KalVista Pharmaceuticals is focused on developing innovative treatments for hereditary angioedema (HAE) through its lead investigational product, sebetralstat. This novel oral plasma kallikrein inhibitor represents a significant advancement in the treatment landscape for HAE, as it allows for on-demand management of attacks via a discreet oral dose, contrasting with existing injectable therapies. Sebetralstat works by selectively inhibiting plasma kallikrein, a key player in the kallikrein-kinin system (KKS), which is responsible for the symptoms associated with HAE. The company has successfully completed a pivotal Phase 3 clinical trial, demonstrating the efficacy and safety of sebetralstat, and is preparing to file a New Drug Application with the U.S. FDA.

KalVista's scientific approach combines deep expertise in the biology of the KKS and Factor XIIa with a strong focus on small molecule drug discovery. The company aims to shift the treatment paradigm from injectable to oral therapies, addressing the unmet needs of patients suffering from HAE and other diseases linked to KKS overactivation. By targeting the KKS, KalVista is not only advancing treatments for HAE but also exploring potential applications for other conditions, such as diabetic macular edema and chronic inflammatory diseases. Their commitment to innovation is supported by a team of experienced scientists dedicated to optimizing oral drug delivery and enhancing patient outcomes.

United States

KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.

Cardiovascular Diseases

Genetic Diseases

Hematologic Diseases

Kalvista Pharmaceuticals

Hereditary angioedema

Rare diseases

Rare genetic disease

KVD900 is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE), with a Phase 2 clinical trial enrollment complete. The completed first-in-human Phase 1 trial, investigated the safety, tolerability and exposure to KVD900. The placebo-controlled study recruited 84 healthy volunteers and included single-ascending dose, formulation and food-effect cross-over phases. A total of 68 subjects received KVD900 and of those, 18 received the maximum 600 mg dose. No serious adverse events (SAEs) were reported, and of the 45 adverse events (AEs), 19 were treatment emergent. All AEs were considered mild except a single AE of headache reported at the 10 mg dose. One GI AE was reported 3 days following dosing during the food-effect phase and was considered unlikely related to treatment.

Sebetralstat (KVD900) (film coated)

KVD824 is our twice-daily oral plasma kallikrein inhibitor for &nbsp;prevention of HAE attacks. We initially evaluated KVD824 in a three-part &nbsp;first-in-human study in which 84 subjects received at least one dose of &nbsp;KVD824. The study evaluated single doses up to 1280 mg, multiple doses &nbsp;up to 640 mg, and the effect of food on KVD824 pharmacokinetics.
<a href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-provides-update-oral-hereditary-0">Source</a>

KVD824 (plasma kallikrein enzyme inhibitor) 

Dementia

Diabetes

Diabetic macular edema

Frontotemporal dementia with C9orf72 mutation

KVD001 is a small molecule plasma kallikrein inhibitor administered by intravitreal injection.
<a href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-reports-phase-2-clinical-trial-results">Source</a>

Kalvista Pharmaceuticals

Company Details